Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy

BACKGROUND: Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1β-mediated pathways. We sought to characterize the molecular response to canakinumab and evaluate potential markers of response using samples from two pivotal trials in systemic juvenile idiopathic ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Brachat, Arndt H., Grom, Alexei A., Wulffraat, Nico, Brunner, Hermine I., Quartier, Pierre, Brik, Riva, McCann, Liza, Ozdogan, Huri, Rutkowska-Sak, Lidia, Schneider, Rayfel, Gerloni, Valeria, Harel, Liora, Terreri, Maria, Houghton, Kristin, Joos, Rik, Kingsbury, Daniel, Lopez-Benitez, Jorge M., Bek, Stephan, Schumacher, Martin, Valentin, Marie-Anne, Gram, Hermann, Abrams, Ken, Martini, Alberto, Lovell, Daniel J., Nirmala, Nanguneri R., Ruperto, Nicolino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5260050/
https://www.ncbi.nlm.nih.gov/pubmed/28115015
http://dx.doi.org/10.1186/s13075-016-1212-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5260050/
https://www.ncbi.nlm.nih.gov/pubmed/28115015
http://dx.doi.org/10.1186/s13075-016-1212-x

Ejemplares similares